Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis

NACompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

October 10, 2020

Primary Completion Date

July 26, 2022

Study Completion Date

August 30, 2022

Conditions
Coronary Artery DiseaseIn Stent Restenosis
Interventions
DEVICE

drug-coated balloon Catheter

All eligible subjects will be assigned randomly to study group or control group, receive PTCA.

Trial Locations (16)

Unknown

Anhui Provincal Hospital, Hefei

Beijing Tiantan Hospital, Capital Medical University, Beijing

Meizhou People's Hospital, Meizhou

Cangzhou Central Hospital, Cangzhou

Daqing Oilfield General Hospital, Daqing

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Nanjing First Hospital, Nanjing

The First Bethune Hospital of Jilin University, Changchun

The Second Hospital of Jilin University, Changchun

General Hospital of Northern Theater Command, Shenyang

Shandong Provincial Hospital, Jinan

Ruijin Hospital,Shanghai Jiaotong University,School of medicine, Shanghai

Shanghai Chest Hospital, Shanghai

Shanxi Cardiovascular Hospital, Taiyuan

Tianjin Chest Hospital, Tianjin

Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

CCRF Inc., Beijing, China

INDUSTRY

lead

B. Braun Medical International Trading Company Ltd.

INDUSTRY

NCT04240444 - Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis | Biotech Hunter | Biotech Hunter